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Abstract
Introduction Cardiovascular molecular imaging is a rapidly
evolving field of research, aiming to image and quantify
molecular and cellular targets in vivo. MR imaging has
some inherent properties that make it very suitable for
cardiovascular molecular imaging. Until now, only a
limited number of studies have been published on cardio-
vascular molecular imaging using MR imaging.
Review In the current review, MR techniques that have
already shown potential are discussed. Metabolic MR
imaging can be performed by 31P-MR spectroscopy, 23Na
MR spectroscopy and 1H-MR spectroscopy; some exam-
ples are shown. Furthermore, a concise overview is given
of several aspecific and specific contrast agents for
cardiovascular molecular MR imaging, such as gadolini-
um-based contrast agents, iron oxide MR contrast agents
and fibrin-targeted MR contrast agents.
Conclusion We expect that in the next decade currently
promising MR molecular imaging agents will be introduced
into the clinical arena to guide diagnosis and therapy of
cardiovascular disease.
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Introduction
Conventional imaging modalities, including magnetic
resonance (MR), are primarily based on anatomical,
functional or metabolic properties to study (patho)physi-
ology. Molecular imaging is a rapidly evolving field of
research, aiming to image and quantify molecular and
cellular targets in vivo. Molecular imaging can be applied
to a wide range of scientific and clinical fields of interest.
One of the most promising applications of molecular
imaging is in the field of cardiovascular imaging. Imaging
of cardiac anatomy, dimensions and function has some
limitations concerning, for example, prediction of therapy
outcome. Addition of specific information on, for instance,
plaque composition and total plaque burden can be very
helpful in guiding therapy.
Imaging of molecular processes is desirable because
cardiovascular disease may be detected earlier, risk strati-
fication may be more accurate, monitoring of innovative
therapies may be improved, or a more accurate prognosis
may be provided [1].
MR imaging has some inherent properties that make it
very suitable for cardiovascular molecular imaging. The
interaction between inherent tissue properties and specific
contrast agents may lead to more specific clinical con-
clusions and prediction of therapy outcome. Thereby,
cardiovascular molecular MR imaging may help in diag-
nosing cardiovascular disease, and in deciding whether
expected beneficial effects of (invasive) therapy counter-
balance the risk of complications of therapy.
A conventional approach to molecular MR imaging
concerns MR spectroscopy. Furthermore, there are two
main innovative contrast agents that may be used clinically
soon: (1) iron oxide MR contrast agents and (2) fibrin-
targeted MR contrast agents.
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MR spectroscopy
MR spectroscopy (MRS) allows non-invasive character-
isation of myocardial metabolism. In principle, MRS is a
pure form of molecular ‘imaging’ technique. Clinically,
several nuclei allow noninvasive MRS of the heart.
Initially, human MRS research was focussed on the 31P
nucleus to study high-energy phosphate metabolism. An
example concerning the effects of diabetes type 2 on
myocardial high-energy phosphate metabolism is shown in
Fig. 1 [2]. Another interesting new application of 31P-MRS
was published by Smith et al. [3], who measured
myocardial creatine kinase (CK) metabolite concentrations
and adenosine triphosphate synthesis through CK, the
primary energy reserve of the heart, to test the hypothesis
that ATP flux through CK is impaired in patients with left
ventricular hypertrophy (LVH) and chronic heart failure. It
turned out that myocardial ATP levels were normal, but
creatine phosphate levels were 35% lower in LVH patients
than in normal subjects. Furthermore, the myocardial CK
rate constant was normal in LVH, but halved in patients
with LVH combined with chronic heart failure. Thereby,
they could show that it is not the relative or absolute CK
metabolite pool size but rather the kinetics of ATP turnover
through CK that distinguishes failing from non-failing
hypertrophic hearts. These observations support the hy-
pothesis that a deficit in myofibrillar energy delivery
contributes to chronic heart failure pathophysiology in
human LVH. The same technique was applied by Weiss et
al. to study ATP flux through CK in the normal, stressed
and failing human heart [4]. The latter studies are elegant
examples of the capability of MR to measure non-
invasively the concentration of metabolites and even the
rate constant of enzyme turnover.
Another interesting application of metabolic imaging is
23Na MR imaging, as show by Jansen et al. They applied
this innovative spectroscopic imaging technique as a
diagnostic modality for early detection of myocardial
ischaemia and viability in a rat model [5]. They tested
whether 23Na MR imaging can be used to assess viability
after low-flow ischaemia. 23Na MR chemical shift imaging
was alternated with 23Na MR spectroscopy. Na image
intensity increased with increasing severity of ischaemia.
23Na image intensity at end low-flow ischaemia was well
correlated with CK release during reperfusion, as well as
with infarct size. Therefore, their study indicates that 23Na
MR imaging is a promising tool for the assessment of
myocardial viability. Ouwerkerk et al. applied 23Na MR
imaging to measure cardiac tissue sodium concentrations in
the human myocardium [6]. They used a surface coil at
1.5 T MR to non-invasively quantify regional myocardial
sodium concentrations in the left ventricular free wall,
septum and adipose tissue. Their 23Na MR imaging results
were consistent with prior invasive measurements on
biopsy and autopsy specimens.
In the past, 1H-MRS of the myocardium was first applied
to non-invasively study creatine depletion in non-viable
infarcted myocardium [7]. Total creatine was measured in
the posterior and anterior left ventricle and septum, and was
significantly lower in regions of infarction than in non-
infarcted regions of myocardium in patients or in the
myocardium of healthy controls. Therefore, they showed
for the first time that spatially localised 1H-MRS can be
used to measure total creatine non-invasively throughout
the human heart. The detection of regional creatine
depletion may provide a metabolic means to distinguish
healthy from infarcted non-viable myocardium.
Szczepaniak et al. used 1H-MRS to measure myocardial
lipid content [8]. Studies in rat tissue ex vivo and in healthy
humans in vivo provided evidence that 1H-MRS constitutes
a reproducible technique for the measurement of myocar-
dial triglyceride. Increased myocardial triglyceride content
was accompanied by elevated LV mass and suppressed
septal wall thickening as measured by cardiac imaging.
More recently, 1H-MRS of the human myocardium was
improved by implementing the respiratory navigator tech-
nique to monitor diaphragmatic motion, and thereby correct
data acquisition prospectively for breathing motion. First
(unpublished) results from our institution show improved
reproducibility of human cardiac 1H-MRS measurements
Fig. 1 Left panel: planscan of
the volume of interest on trans-
verse and sagittal spin-echo MR
images. Right panel: phospho-
rus-31 magnetic resonance
spectroscopy (31P-MRS)
obtained at rest from the anterior
left ventricular wall in a patient
with diabetes type 2 (left) and a
healthy subject (right). Note the
decreased signal amplitude of
phosphocreatine in the type 2
diabetes patient. Courtesy of
Diamant et al. [2]
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when using the respiratory navigator technique, as com-
pared with conventional continuous breathing. Respiratory
navigator gated 1H-MRS was recently applied in an
experimental setting in our institution to evaluate the effects
of a very low calorie diet on myocardial triglyceride
content. First (unpublished) results show that after a short
very low calorie diet, there is an increase in intramyocardial
triglyceride content (Fig. 2).
Gadolinium-based contrast agents
Gadolinium-based contrast agents can be applied to study
regional myocardial perfusion. After a rapid intravenous
contrast injection, there is marked signal enhancement first
in the RV cavity, then in the LV cavity, and subsequently in
the LV myocardium [9]. The peak signal intensity is related
to the concentration of the contrast agent in the local tissue
and is directly proportional to the coronary blood flow.
Perfusion MR at rest and after infusion of pharmacological
agents (adenosine and persantine) have been compared with
standard methods (angiography or radionuclide scintigra-
phy) and demonstrated reasonable sensitivity (67–83%) and
specificity (75–100%) [9].
Currently, multiple MR imaging techniques are available
to assess myocardial viability. Cardiovascular MR imaging
can be used to assess end-diastolic wall thickness and
contractile function at rest [10]. Segments with an end-
diastolic wall thickness <6 mm most likely represent
transmural scar formation, and contractile function will
not improve after myocardial revascularisation. Dobut-
amine MR imaging can be used to evaluate contractile
Fig. 3 Left panel: short-axis MR images at rest and during dobut-
amine stress. Note the lack of improvement in myocardial wall motion
in the anteroseptal region when dobutamine stress is applied. Right
panel: delayed gadolinium contrast-enhanced MR images in two-
chamber, four-chamber and short-axis views. Note the almost trans-
mural delayed enhancement of the anteroseptal/apical region,
corresponding to the region without contractile response due to
dobutamine stress in the left panel. The anteroseptal region is
considered as ‘non-viable’ myocardial tissue
Fig. 2 The surface coil was
positioned just below the mitral
valve level of the heart (a, b).
Spectroscopic volume localisa-
tion in the interventricular sep-
tum on four-chamber (c) and
short axis (d) views. Special
care was taken to avoid con-
tamination from epicardial fat.
(e) Typical water-suppressed
1H-MR spectrum of myocardial
tissue located in the interven-
tricular septum. Peak heights are
in arbitrary units
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reserve, in a similar manner to dobutamine echocardiogra-
phy. Gadolinium contrast-enhanced MR imaging [11]
allows for detection of the extent and transmurality of scar
tissue (Fig. 3). Recently reported sensitivity and specificity
are in the range of 74% and 82% respectively.
Based on as yet unpublished scientific developments, it is
expected that gadolinium-based delayed enhancement of the
vessel wall may become reality. This MR imaging technique
may allow fast total body screening for total plaque burden,
an important predictor for morbidity and mortality.
In general, gadolinium-based contrast agents are not
perfectly suited for molecular imaging because of the
inherent high threshold of detectability. Therefore, new
contrast agents are under development to potentiate the
effect of distortion of the magnetic field.
Iron oxide MR contrast agents
Superparamagnetic iron oxide (SPIO) particles can be
detected at micromolar concentrations of iron, and offer
sufficient sensitivity for MR imaging [12]. SPIO-based
cellular imaging has become an established technique to
label and detect cells of interest. Imaging of macrophage
activity was the initial and is still the most significant
application, with several products either approved for or in
Fig. 4 Detection of delivery
and migration of Feridex-la-
belled myocardial stem cells in a
swine model. Hypointense
lesions in spin-echo (SE),
gradient-echo (GRE) and
delayed-enhanced (Delayed)
MR imaging (upper panel) of
injection sites (arrows) within
24 h of intramyocardial injec-
tion. Cells were injected in the
myocardial infarct (MI). Long-
axis MR images (lower panel)
show hypointense lesions
(arrows) caused by labelled
myocardial stem cells acquired
within 24 h and 1 week. LV left
ventricle, RV right ventricle.
Courtesy of Bulte and
Kraitchman [12]
Fig. 5 Coronary thrombus vis-
ualisation with a fibrin-targeted
molecular MR imaging contrast
agent. Left panel: double-
oblique white blood coronary
MR angiography (multiplanar
reconstruction) demonstrating
the lumen of the left anterior
descending artery with bright
signal (arrowheads). Right
panel: double-oblique MR
images after administration of
the fibrin-targeted contrast agent
(multiplanar reconstruction,
same orientation). Note the in-
creased signal (arrow) in the left
anterior descending coronary
artery, corresponding to throm-
bus. Courtesy of Spuentrup et al.
[14]
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clinical trials [12]. Another exciting application of SPIOs is
labelling of myocardial stem cells. In a swine model for
myocardial infarction, magnetically labelled stem cells were
injected in the infarcted myocardial region (Fig. 4). Using
delayed contrast-enhanced MR imaging, the infarcted area
can be identified with high accuracy. New technical
developments may even allow specific delivery of magnet-
ically labelled therapeutics to the infarcted myocardial
region [12]. Combined with measurements of myocardial
function, MR imaging seems an excellent modality for
planning, delivery and follow-up of myocardial stem cells
as therapy for ischaemic heart disease.
Another promising application of SPIO MR imaging is
visualisation of vessel wall inflammation. SPIOs are
‘digested’ by macrophages, involved in inflammatory
processes. Imaging of the SPIO-induced magnetic inhomo-
geneities allows for imaging of inflammation. Such an
approach is currently only available in a research setting; it
Fig. 6 Molecular MR imaging
of atrial clot in a swine model.
The left panel shows pre-con-
trast (upper) and post-contrast
(lower) coronal images. Note
the presence of high MR signal
in the area of the right atrium,
indicating an atrial clot. The
right panel shows increased MR
signal in the left atrium (LA),
corresponding to a left atrial clot
(arrow). These clots are poten-
tial sources for more distal em-
boli. LV left ventricle. Courtesy
of Spuentrup et al. [14]
Fig. 7 Examples of molecular
MR imaging of pulmonary em-
bolus. Two examples are shown,
each consisting of three adjacent
coronal slices (horizontal). The
MR imaging technique is such
that signal from surrounding
blood pool and lung parenchy-
ma is suppressed. The upper
row shows pulmonary embolus
(arrow) in the right lower lobe.
The lower panel shows bilateral
pulmonary emboli (arrows) after
intravenous administration of fi-
brin-targeted MR imaging con-
trast agent. Courtesy of
Spuentrup et al. [14]
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is, however, expected that these contrast agents will become
available for clinical application soon.
Fibrin-targeted MR contrast agents
Exciting recent developments allow selective and non-
invasive molecular MR imaging of thrombus [13]. The
principle of the contrast agent is that it is targeted to fibrin.
In an elegant study by Spuentrup et al., a swine model was
used to test the innovative fibrin-targeted MR imaging
contrast agent, which can be administered intravenously
[14]. The imaging protocol consisted of coronary MR
angiography to demonstrate the lumen of a coronary artery,
combined with molecular thrombus MR imaging. Thereby,
anatomical information could be linked to specific infor-
mation of vessel wall components. In an area of focal
coronary artery stenosis, intraluminal thrombus could be
detected (Fig. 5).
The same contrast agent can be applied to detect, for
example, right atrial thrombus, a potential source of more
distal emboli (Fig. 6). An atrial clot could be visualised
easily with this molecular MR imaging technique, by
intravenous administration of the fibrin-targeted contrast
agent. Furthermore, MR clot imaging can be combined with
functional imaging of the heart in the same imaging
session. An even more exciting application of this fibrin-
targeted contrast agent is detection of pulmonary emboli
(Fig. 7).
The above-described applications of molecular MR
imaging may be especially suitable for fast screening for
cardiovascular disease in an emergency setting. Patients
presenting with chest pain in the emergency room can be
studied by MR imaging to confirm or rule out ischaemic
heart disease or pulmonary embolus. Molecular MR
imaging using fibrin-targeted contrast agents allows selec-
tive visualisation of acute coronary, cardiac and pulmonary
thrombi. Additional functional cardiac imaging can help
determine the functional effects of detected thrombi.
Conclusion
Molecular MR imaging is an exciting and rapidly evolving
new area of cardiovascular imaging. MR imaging seems
very suitable for molecular imaging, although many
technical difficulties have to be overcome. The main
current limitation is the low sensitivity of MR imaging to
detect small changes in magnet homogeneity. We expect
that in the next decade, currently promising MR molecular
imaging agents will be introduced into the clinical arena to
guide diagnosis and therapy of cardiovascular disease.
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